中华病理学杂志
中華病理學雜誌
중화병이학잡지
Chinese Journal of Pathology
2011年
7期
454-459
,共6页
张景敏%孙翠云%于士柱%王虔%安同岭%李艳艳%孔妍玲%温艳军
張景敏%孫翠雲%于士柱%王虔%安同嶺%李豔豔%孔妍玲%溫豔軍
장경민%손취운%우사주%왕건%안동령%리염염%공연령%온염군
神经胶质瘤%微RNAs%细胞周期蛋白依赖激酶6%细胞增殖%细胞凋亡
神經膠質瘤%微RNAs%細胞週期蛋白依賴激酶6%細胞增殖%細胞凋亡
신경효질류%미RNAs%세포주기단백의뢰격매6%세포증식%세포조망
Glioma%MicroRNAs%Cyclin-dependent kinase 6%Cell proliferation%Apoptosis
目的 探讨胶质瘤细胞中miR-218及细胞周期蛋白依赖性激酶6(CDK6)表达变化的相互关系及其对肿瘤细胞增殖及凋亡的影响.方法 采用组织微阵列、锁定寡核苷酸探针原位杂交及免疫组织化学(ABC法)方法,检测60例不同级别胶质瘤组织标本及10例对照脑组织中miR-218、CDK6及Ki-67抗原的表达状况,并分析三者之间的相互关系;胶质母细胞瘤细胞系(U87MG)分别被转染阴性对照序列(对照组)及miR-218 mimics(mimics组),采用即时定量聚合酶链反应(qRT-PCR)及免疫细胞化学方法 分别检测两组细胞中的miR-218水平及CDK6和Ki-67表达变化,用单细胞凝胶电泳检测凋亡细胞.结果 对照组、Ⅰ～Ⅱ级、Ⅲ级和Ⅳ级胶质瘤组miR-218阳性标记指数(LI,%)分别为22.45±0.59、4.00±1.07、1.87±1.06、0.94±0.78,四组间差异均有统计学意义(P<0.05);各组CDK6 LI分别为7.25±1.20、16.71±0.80、24.43±0.62、32.05±0.43,对照组与各胶质瘤组间及Ⅳ级组与Ⅰ～Ⅱ级组间差异有统计学意义(P<0.01);各组Ki-67阳性细胞密度分别为0.00±0.00、9.30±3.48、31.15±9.44、60.15±13.60[(±s)/0.05 mm2],各组间差异均有统计学意义(P<0.01);miR-218 LI与CDK6 LI及Ki-67阳性细胞密度间均呈显著性负相关(r=-0.480,-0.534,P<0.01),后两者间呈显著性正相关(r=0.530,P<0.01).mimics组的miR-218水平明显高于对照组,其CDK6及Ki-67 LI(14.74±1.19、30.88±3.31)均明显低于对照组(79.06±2.07、64.94±3.96,P<0.01),而凋亡指数(68.44±7.05)明显高于对照组(13.04±0.97),以上各指标两组间差异均有统计学意义(P<0.01).结论 miR-218表达水平是评价胶质瘤良恶性程度的重要参考指标;其表达异常减少可导致胶质瘤细胞CDK6表达及增殖活性增强;补充外源性miR-218可有效下调恶性胶质瘤细胞CDK6表达、抑制其增殖和促进其凋亡,故在恶性胶质瘤基因治疗中具有重要的潜在应用价值.
目的 探討膠質瘤細胞中miR-218及細胞週期蛋白依賴性激酶6(CDK6)錶達變化的相互關繫及其對腫瘤細胞增殖及凋亡的影響.方法 採用組織微陣列、鎖定寡覈苷痠探針原位雜交及免疫組織化學(ABC法)方法,檢測60例不同級彆膠質瘤組織標本及10例對照腦組織中miR-218、CDK6及Ki-67抗原的錶達狀況,併分析三者之間的相互關繫;膠質母細胞瘤細胞繫(U87MG)分彆被轉染陰性對照序列(對照組)及miR-218 mimics(mimics組),採用即時定量聚閤酶鏈反應(qRT-PCR)及免疫細胞化學方法 分彆檢測兩組細胞中的miR-218水平及CDK6和Ki-67錶達變化,用單細胞凝膠電泳檢測凋亡細胞.結果 對照組、Ⅰ～Ⅱ級、Ⅲ級和Ⅳ級膠質瘤組miR-218暘性標記指數(LI,%)分彆為22.45±0.59、4.00±1.07、1.87±1.06、0.94±0.78,四組間差異均有統計學意義(P<0.05);各組CDK6 LI分彆為7.25±1.20、16.71±0.80、24.43±0.62、32.05±0.43,對照組與各膠質瘤組間及Ⅳ級組與Ⅰ～Ⅱ級組間差異有統計學意義(P<0.01);各組Ki-67暘性細胞密度分彆為0.00±0.00、9.30±3.48、31.15±9.44、60.15±13.60[(±s)/0.05 mm2],各組間差異均有統計學意義(P<0.01);miR-218 LI與CDK6 LI及Ki-67暘性細胞密度間均呈顯著性負相關(r=-0.480,-0.534,P<0.01),後兩者間呈顯著性正相關(r=0.530,P<0.01).mimics組的miR-218水平明顯高于對照組,其CDK6及Ki-67 LI(14.74±1.19、30.88±3.31)均明顯低于對照組(79.06±2.07、64.94±3.96,P<0.01),而凋亡指數(68.44±7.05)明顯高于對照組(13.04±0.97),以上各指標兩組間差異均有統計學意義(P<0.01).結論 miR-218錶達水平是評價膠質瘤良噁性程度的重要參攷指標;其錶達異常減少可導緻膠質瘤細胞CDK6錶達及增殖活性增彊;補充外源性miR-218可有效下調噁性膠質瘤細胞CDK6錶達、抑製其增殖和促進其凋亡,故在噁性膠質瘤基因治療中具有重要的潛在應用價值.
목적 탐토효질류세포중miR-218급세포주기단백의뢰성격매6(CDK6)표체변화적상호관계급기대종류세포증식급조망적영향.방법 채용조직미진렬、쇄정과핵감산탐침원위잡교급면역조직화학(ABC법)방법,검측60례불동급별효질류조직표본급10례대조뇌조직중miR-218、CDK6급Ki-67항원적표체상황,병분석삼자지간적상호관계;효질모세포류세포계(U87MG)분별피전염음성대조서렬(대조조)급miR-218 mimics(mimics조),채용즉시정량취합매련반응(qRT-PCR)급면역세포화학방법 분별검측량조세포중적miR-218수평급CDK6화Ki-67표체변화,용단세포응효전영검측조망세포.결과 대조조、Ⅰ～Ⅱ급、Ⅲ급화Ⅳ급효질류조miR-218양성표기지수(LI,%)분별위22.45±0.59、4.00±1.07、1.87±1.06、0.94±0.78,사조간차이균유통계학의의(P<0.05);각조CDK6 LI분별위7.25±1.20、16.71±0.80、24.43±0.62、32.05±0.43,대조조여각효질류조간급Ⅳ급조여Ⅰ～Ⅱ급조간차이유통계학의의(P<0.01);각조Ki-67양성세포밀도분별위0.00±0.00、9.30±3.48、31.15±9.44、60.15±13.60[(±s)/0.05 mm2],각조간차이균유통계학의의(P<0.01);miR-218 LI여CDK6 LI급Ki-67양성세포밀도간균정현저성부상관(r=-0.480,-0.534,P<0.01),후량자간정현저성정상관(r=0.530,P<0.01).mimics조적miR-218수평명현고우대조조,기CDK6급Ki-67 LI(14.74±1.19、30.88±3.31)균명현저우대조조(79.06±2.07、64.94±3.96,P<0.01),이조망지수(68.44±7.05)명현고우대조조(13.04±0.97),이상각지표량조간차이균유통계학의의(P<0.01).결론 miR-218표체수평시평개효질류량악성정도적중요삼고지표;기표체이상감소가도치효질류세포CDK6표체급증식활성증강;보충외원성miR-218가유효하조악성효질류세포CDK6표체、억제기증식화촉진기조망,고재악성효질류기인치료중구유중요적잠재응용개치.
Objectives To investigate the relationship between the expression of miR-218 and CDK6 in glioma cells, and their biological impacts on the tumor cell proliferation and apoptosis. MethodsExpression levels of miR-218 as well as CDK6 and Ki-67 proteins were analyzed in 60 cases of gliomas with various grades and 10 control brain tissue samples by tissue microarray, locked oligonucleotide probe in situ hybridization and immunohistochemistry. Glioblastoma multiform cell line (U87MG) was transfected with miR-218 mimics (mimics group) and a control sequence (control group), followed by qRT-PCR detection of miR-218 and immunocytochemical stain of CDK6 and Ki-67, respectively. Single cell gel electrophoresis was used to detect the presence of apoptotic cell. Results The miR-218 labeling indexes (LI) were statistically different (P<0.05) among all groups including control (22.45±0.59) and various glioma groups (grades Ⅰ-Ⅱ 4.00±1.07, grade Ⅲ 1.87±1.06 and grade Ⅳ 0.94±0.78, respectively). The CDK6 LI of the four groups was 7.25±1.20, 16.71±0.80, 24.43±0.62 and 32.05±0.43, respectively. Significant differences existed between the control group and the glioma groups, and between grade Ⅳ and grades Ⅰ-Ⅱ glioma groups (P<0.01). Ki-67 positive cell densities of the above four groups (0.00±0.00, 9.30±3.48, 31.15±9.44 and 60.15±13.60) were significantly different from one and another (P<0.01). The expression of miR-218 negatively correlated with CDK-6 LI (r=-0.480, P<0.01) and Ki-67 positive cell density (r=-0.534, P<0.01), while the latter two positively correlated with each other (r=0.530, P<0.01). U87MG transfection experiment showed that the miR-218 level of the mimics group was significantly higher than that of the control group (P<0.01). CDK6 and Ki-67 LI of the mimics group (14.74±1.19 and 30.88±3.31) were significantly lower than those of the control group (79.06±2.07 and 64.94±3.96, P<0.01), whilst its apoptotic index (AI) (68.44±7.05) was significantly higher than that of the control group (13.04±0.97, P<0.01). Conclusions The expression level of miR-218 is an important reference indicator for the assessment of the grade of gliomas. An aberrant decrease of its expression may lead to an increase of the CDK6 expression and proliferative activity of giloma cells. Introducing exogenous miR-218 may effectively down-regulate the CDK6 expression, inhibit cell proliferation and induce apoptosis of malignant giloma cells. These findings imply that miR-218 may serve as a therapeutic agent against malignant glioma.
